Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 3
2004 2
2005 2
2006 3
2007 4
2008 7
2009 5
2010 9
2011 7
2012 10
2013 10
2014 20
2015 12
2016 10
2017 11
2018 4
2019 10
2020 10
2021 16
2022 5
2023 10
2024 15
2025 19
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

177 results

Results by year

Filters applied: . Clear all
Page 1
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.
Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/MORPHO Study Investigators. Levis MJ, et al. Among authors: devine sm. J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12. J Clin Oncol. 2024. PMID: 38471061 Free PMC article. Clinical Trial.
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Oshima MU, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly LS, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Chen C, Hasabou N, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Mendizabal A, Devine SM, Horowitz MM, Chen YB. Levis MJ, et al. Among authors: devine sm. Blood. 2025 May 8;145(19):2138-2148. doi: 10.1182/blood.2024025154. Blood. 2025. PMID: 39775763 Free article. Clinical Trial.
DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.
Dillon LW, Gui G, Page KM, Ravindra N, Wong ZC, Andrew G, Mukherjee D, Zeger SL, El Chaer F, Spellman S, Howard A, Chen K, Auletta J, Devine SM, Jimenez Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Weisdorf DJ, Hourigan CS. Dillon LW, et al. Among authors: devine sm. JAMA. 2023 Mar 7;329(9):745-755. doi: 10.1001/jama.2023.1363. JAMA. 2023. PMID: 36881031 Free PMC article.
Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR.
Jimenez Jimenez AM, Spellman SR, Politikos I, McCurdy SR, Devine SM, Malki MMA, Bolon YT, Lee SJ, Dehn J, Pidala J, Maiers M, Askar M, Malmberg C, Auletta JJ, Stefanski H, Broglie L, Qayed M, Horwitz M, Wilder JS, Gooptu M, Mehta RS, Fernandez-Viña M, Shaw BE, Shaffer BC. Jimenez Jimenez AM, et al. Among authors: devine sm. Transplant Cell Ther. 2025 Dec;31(12):973-988. doi: 10.1016/j.jtct.2025.07.004. Epub 2025 Jul 5. Transplant Cell Ther. 2025. PMID: 40619101 Free PMC article. Review.
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME. Scott BL, et al. Among authors: devine sm. J Clin Oncol. 2017 Apr 10;35(11):1154-1161. doi: 10.1200/JCO.2016.70.7091. Epub 2017 Feb 13. J Clin Oncol. 2017. PMID: 28380315 Free PMC article. Clinical Trial.
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia.
Dillon LW, Gui G, Ravindra N, Andrew G, Mukherjee D, Wong ZC, Huang Y, Gerhold J, Holman M, D'Angelo J, Miller J, Higgins J, Salk JJ, Auletta JJ, El Chaer F, Devine SM, Jimenez-Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Spellman SR, Zeger SL, Page KM, Hourigan CS. Dillon LW, et al. Among authors: devine sm. JAMA Oncol. 2024 Aug 1;10(8):1104-1110. doi: 10.1001/jamaoncol.2024.0985. JAMA Oncol. 2024. PMID: 38696205 Free PMC article.
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.
Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, Geller N, Giralt S, Heslop HE, Horowitz MM, Jones RJ, Litzow MR, Mendizabal A, Muffly L, Nemecek ER, O'Donnell L, O'Reilly RJ, Palencia R, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales MA. Luznik L, et al. Among authors: devine sm. J Clin Oncol. 2022 Feb 1;40(4):356-368. doi: 10.1200/JCO.21.02293. Epub 2021 Dec 2. J Clin Oncol. 2022. PMID: 34855460 Free PMC article. Clinical Trial.
Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research Registry.
Cusatis R, Litovich C, Feng Z, Allbee-Johnson M, Kapfhammer M, Mattila D, Akinola I, Phelan R, Broglie L, Auletta JJ, Steinert P, Bolon YT, Akhtar O, Bloomquist J, Chen M, Devine SM, Bupp C, Hamadani M, Hengen M, Jaglowski S, Kaur M, Kuxhausen M, Lee SJ, Moskop A, Page KM, Pasquini MC, Rizzo D, Saber W, Spellman SR, Stefanski HE, Tuschl E, Yusuf R, Zhan K, Flynn KE, Shaw BE. Cusatis R, et al. Among authors: devine sm. Transplant Cell Ther. 2024 Sep;30(9):917.e1-917.e12. doi: 10.1016/j.jtct.2024.06.021. Epub 2024 Jun 27. Transplant Cell Ther. 2024. PMID: 38944153 Free PMC article.
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors.
Shaffer BC, Gooptu M, DeFor TE, Maiers M, Bolaños-Meade J, Abboud R, Briggs AD, Khimani F, Modi D, Newcomb R, Shpall EJ, Bupp C, Spellman SR, Stefanski HE, Shaw BE, Auletta JJ, Devine SM, Jimenez Jimenez AM, Al Malki MM. Shaffer BC, et al. Among authors: devine sm. J Clin Oncol. 2024 Oct;42(28):3277-3286. doi: 10.1200/JCO.24.00184. Epub 2024 Jul 17. J Clin Oncol. 2024. PMID: 39018507 Free PMC article.
Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR.
Spellman SR, Xu K, Oloyede T, Ahn KW, Akhtar O, Bolon YT, Broglie L, Bloomquist J, Bupp C, Chen M, Devine SM, El-Jurdi N, Hamadani M, Hengen M, Huppler AH, Jaglowski S, Kuxhausen M, Lee SJ, Moskop A, Page KM, Pasquini MC, Perez W, Phelan R, Rizzo D, Saber W, Stefanski HE, Steinert P, Tuschl E, Visotcky A, Vogel R, Auletta JJ, Shaw BE, Allbee-Johnson M. Spellman SR, et al. Among authors: devine sm. Transplant Cell Ther. 2025 Aug;31(8):505-532. doi: 10.1016/j.jtct.2025.05.014. Epub 2025 May 19. Transplant Cell Ther. 2025. PMID: 40398621 Review.
177 results